Assessment of the Japan Generics Industry
Executive Summary
While Japan is the second largest pharma market globally, it has a very low penetration rate of generic drugs. The country’s government has set an ambitious goal to enhance the generics penetration to at least 30% of all ethical drugs by the end of 2012. The segment’s growth is expected to be driven by various factors such as a rapidly aging population, government initiatives to reduce healthcare spending and key drug patent expiries. The huge potential of this market has also attracted foreign players to this relatively untapped market, as they have collaborated or acquired stake in some of the domestic companies. Many Japanese hospitals are adopting the Diagnosis Procedure Combination (DPC), a flat-fee system that is promoting the penetration of generics in Japan.
Why should the report be purchased?
Our report ‘Assessment of the Japan Generics Industry’ analyzes the structure and positioning of the generics sector within the Japanese pharmaceutical industry. It highlights key trends and drivers of the generics drug industry in Japan. It analyses the key challenges being faced and the government initiatives being taken to overcome barriers and support the growth of this segment. A detailed study of key players in the market has also been presented.
Research methodology and delivery time
Smart Research Insights has conducted in depth secondary research to arrive at key insights. Data collected from key industry sources has been analyzed impartially to present a clear picture of the industry. All recent developments which impact the sector dynamics have been captured and used to support the research hypothesis.
The report is available as single-site single-user license. The delivery time for the electronic version of the report is 3 business days as each copy undergoes thorough quality check and is updated with the most recent information available. The delivery time for hard copies is approximately 3-5 business days, as each hard copy is custom printed for the client.
About Smart Research Insights (SRI)
SRI is a research organization which specializes in niche sector reports. We have a team of dedicated researchers with rich experience across industry segments that focus on delivering high quality analysis. We are also engaged in providing customized research solutions and company reports.
While Japan is the second largest pharma market globally, it has a very low penetration rate of generic drugs. The country’s government has set an ambitious goal to enhance the generics penetration to at least 30% of all ethical drugs by the end of 2012. The segment’s growth is expected to be driven by various factors such as a rapidly aging population, government initiatives to reduce healthcare spending and key drug patent expiries. The huge potential of this market has also attracted foreign players to this relatively untapped market, as they have collaborated or acquired stake in some of the domestic companies. Many Japanese hospitals are adopting the Diagnosis Procedure Combination (DPC), a flat-fee system that is promoting the penetration of generics in Japan.
Why should the report be purchased?
Our report ‘Assessment of the Japan Generics Industry’ analyzes the structure and positioning of the generics sector within the Japanese pharmaceutical industry. It highlights key trends and drivers of the generics drug industry in Japan. It analyses the key challenges being faced and the government initiatives being taken to overcome barriers and support the growth of this segment. A detailed study of key players in the market has also been presented.
Research methodology and delivery time
Smart Research Insights has conducted in depth secondary research to arrive at key insights. Data collected from key industry sources has been analyzed impartially to present a clear picture of the industry. All recent developments which impact the sector dynamics have been captured and used to support the research hypothesis.
The report is available as single-site single-user license. The delivery time for the electronic version of the report is 3 business days as each copy undergoes thorough quality check and is updated with the most recent information available. The delivery time for hard copies is approximately 3-5 business days, as each hard copy is custom printed for the client.
About Smart Research Insights (SRI)
SRI is a research organization which specializes in niche sector reports. We have a team of dedicated researchers with rich experience across industry segments that focus on delivering high quality analysis. We are also engaged in providing customized research solutions and company reports.
1. INTRODUCTION: JAPAN PHARMACEUTICAL MARKET
2. JAPAN GENERIC DRUGS INDUSTRY: OVERVIEW
a. Performance Analysis
b. Regulatory Environment
3. EMERGING TRENDS & DRIVERS
4. INDUSTRY CHALLENGES
5. COMPETITIVE LANDSCAPE
a. Taiyo Pharmaceutical
b. Sawai Pharmaceuticals
c. TOWA Pharmaceutical
d. Nichi-Iko
e. Nippon Chemiphar
6. FUTURE OUTLOOK
7. RESEARCH METHODOLOGY
8. ABOUT SMART RESEARCH INSIGHTS
2. JAPAN GENERIC DRUGS INDUSTRY: OVERVIEW
a. Performance Analysis
b. Regulatory Environment
3. EMERGING TRENDS & DRIVERS
4. INDUSTRY CHALLENGES
5. COMPETITIVE LANDSCAPE
a. Taiyo Pharmaceutical
b. Sawai Pharmaceuticals
c. TOWA Pharmaceutical
d. Nichi-Iko
e. Nippon Chemiphar
6. FUTURE OUTLOOK
7. RESEARCH METHODOLOGY
8. ABOUT SMART RESEARCH INSIGHTS
